Replies to post #243040 on Avid Bioservices Inc (CDMO)

[exwannabe]

Opdivo did well in less then twenty percent of patients ie "responders" pd1 positive patients 20 months.

Opdivo was 17 months O/S in the entire population. And with substantially less serious AEs than docetaxol (and by inference, doce+bavi).

That is the target to beat.

I believe we see complete responses in the durvolumab trial when combined with Bavituximab

Very possible. But that will be a long tough road. Using durvo (vs Opdivo) may make running an early stage trial easier, but the entire road to approval becomes more complicated. I seriously doubt this combo is close to approval this decade.